Early trial tests new shot for skin condition

NCT ID NCT06625177

Summary

This early-stage trial is testing the safety of an experimental medication called TEV-53408 for adults with vitiligo, a condition that causes loss of skin color. The study will involve 38 participants who will receive injections under the skin over 24 weeks, followed by a long monitoring period. The main goal is to see if the treatment is safe and well-tolerated, while also gathering early information on whether it might help repigment the skin.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Teva Investigational Site 12043

    Scottsdale, Arizona, 85260, United States

  • Teva Investigational Site 12044

    Fremont, California, 94538, United States

  • Teva Investigational Site 12045

    Dallas, Texas, 75230, United States

  • Teva Investigational Site 12046

    Pasadena, California, 91101, United States

  • Teva Investigational Site 12047

    Chicago, Illinois, 60614, United States

  • Teva Investigational Site 12048

    Canton, Michigan, 48187, United States

  • Teva Investigational Site 12049

    Miramar, Florida, 33025, United States

  • Teva Investigational Site 12051

    Irvine, California, 92617, United States

  • Teva Investigational Site 12052

    Hot Springs, Arkansas, 71913, United States

  • Teva Investigational Site 12053

    Louisville, Kentucky, 40421, United States

  • Teva Investigational Site 12054

    Portland, Oregon, 97210, United States

  • Teva Investigational Site 12055

    South Jordan, Utah, 84095, United States

  • Teva Investigational Site 12057

    Webster, Texas, 77598, United States

Conditions

Explore the condition pages connected to this study.